Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Neuphoria Therapeutics Inc.NEUP · healthcare
GradeNonecomputable_factors_below_threshold: 4 of 14 inputs computable; 7 are required
Reliability0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$12.5M to $120M assetstotal assets $28.7M[1]
Standard universeinsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, late filer, thin datanot computable: distress, fortress balance sheet
Inputs computable4 of 14
Graded fromfilings received through Sep 18, 202621 days before the rescan; every figure keyed to the SEC receipt date
Last close$3.352026-10-08; market equity $18.1M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$10$20NovDecJanFebMarAprMayJunJulAugSepOct$3.35
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Oct 21, 2024nonen/aQ2

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Sep 18, 2026; the document on sec.gov.

Neuphoria Therapeutics Inc. is a Delaware corporation and a clinical-stage biotechnology company. Following the results of our Phase 3 AFFIRM-1 trial and the restructuring actions taken during fiscal 2026, our activities are focused on completing the proposed merger with Scancell Holdings plc ("Scancell"), preserving cash, maintaining our public-company and contractual obligations, and managing our intellectual property and economic interests in partnered programs. We are currently conducting limited active internal research and development activities focused on our alpha7 nicotinic acetylcholine receptor negative allosteric modulator portfolio.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 129.5%[3-4]
Late filer. found 1 NT 10-K/Q filings in the last eight quarters
Thin data. 4 of 14 grade factors are computable; minimum is 7

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 67.4
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(3.8%)[1,5-7](6.6%)67.48112026-06-30
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 35.5
Twelve-month failure probabilitynot computable0.07%
latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime(14.70)[1,8-13](0.31)69.37562026-06-30
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio27.85x[8-9]2.96x1.78392026-06-30
Growth and financing, sleeve percentile 85.9
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 2
Free cash flow growth, three-year compoundnot computable10.9%
four consecutive annual FCF observations are required; found 0
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three yearsnot computable2.1%
four annual observations are required; found 3
Net share issuance, one year129.5%[3-4]2.5%85.96342026-09-17

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(68.1%)8.0%7hotter than 7 of 100 peers
Distance from 52-week high(82.4%)(31.4%)8closer to its high than 8 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yieldnot computable(1.0%)required accounting or market input is missing
Book value to price1.360.2892pricier than 8 of 100 peers
Sales to price0.060.3120pricier than 80 of 100 peers
Composite equity issuance, five yearsnot computable20.3%a share count from five years earlier is required
Relative strength against the sector, log excess return(1.36)(0.14)7ahead of 7 of 100 peers

Inputs: market equity $18.1M; EBIT -$16.5M; book equity $24.6M; sales $1.2M; cash $19.9M[3].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2026-06-30
Return on assets above zero(47.1%)✗ fail[5,7]
Operating cash flow above zero-$12.4M✗ fail[6]
Return on assets improved(45.7 pts)✗ fail[5,7,14-15]
Operating cash flow exceeds net income$1.1M✓ pass[5-6]
Long-term leverage felln/a[1,7,15]
Current ratio improved2,428.4 pts✓ pass[8-9,16-17]
No new shares issued129.5%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improved(52.5 pts)✗ fail[2,7,15,18]
Cash, filings, liquidity
Cash and equivalents$19.9M[19]
Operating cash flow, four quarters-$12.4M[6,19-22]
Months of runway19.3
Late filings, two years1
NT 10-K or NT 10-Q
Days since last periodic filing21
10-K received Sep 18, 2026
Median daily dollar volume$91,762
63 sessions
Days since newest grade input21

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$28.7M2026-06-302026-09-1810-Kfiling · viewer · series
2revenueus-gaap:Revenues$1.2M2026-06-302026-09-1810-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding5,411,3342026-09-172026-09-1810-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding2,357,6132025-09-292025-09-2910-Kfiling · viewer · series
5net incomeus-gaap:NetIncomeLoss-$13.5M2026-06-302026-09-1810-Kfiling · viewer · series
6operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$12.4M2026-06-302026-09-1810-Kfiling · viewer · series
7assetsus-gaap:Assets$28.6M2025-06-302026-09-1810-Kfiling · viewer · series
8current assetsus-gaap:AssetsCurrent$21.1M2026-06-302026-09-1810-Kfiling · viewer · series
9current liabilitiesus-gaap:LiabilitiesCurrent$756,5812026-06-302026-09-1810-Kfiling · viewer · series
10retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$191.8M2026-06-302026-09-1810-Kfiling · viewer · series
11operating incomeus-gaap:OperatingIncomeLoss-$16.5M2026-06-302026-09-1810-Kfiling · viewer · series
12book equityus-gaap:StockholdersEquity$24.6M2026-06-302026-09-1810-Kfiling · viewer · series
13liabilitiesus-gaap:Liabilities$4.1M2026-06-302026-09-1810-Kfiling · viewer · series
14net incomeus-gaap:NetIncomeLoss-$369,6322025-06-302026-09-1810-Kfiling · viewer · series
15assetsus-gaap:Assets$27.6M2024-06-302025-09-2910-Kfiling · viewer · series
16current assetsus-gaap:AssetsCurrent$15.0M2025-06-302026-09-1810-Kfiling · viewer · series
17current liabilitiesus-gaap:LiabilitiesCurrent$4.2M2025-06-302026-09-1810-Kfiling · viewer · series
18revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$15.6M2025-06-302025-09-2910-Kfiling · viewer · series
19cashus-gaap:CashAndCashEquivalentsAtCarryingValue$19.9M2026-06-302026-09-1810-Kfiling · viewer · series
20operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$13.6M2026-03-312026-05-1510-Qfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$10.2M2025-12-312026-02-1710-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$3.8M2025-09-302025-11-1410-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.